Bayer Presents Latest Data from Oncology Portfolio at 2024 ASCO Annual Meeting
Bayer will showcase latest data for growth driver NUBEQA® (darolutamide) and targeted radionuclide therapy XOFIGO® (radium Ra 223 dichloride) Bayer will also present a late-breaking abstract on the Phase I/II study of BAY 2927088 in patients with HER2- …